Tag: Outlook Therapeutics

The stock has more than doubled since late May, but the coming weeks will determine whether that momentum is sustainable ...

Outlook Therapeutics enters a high-stakes July with two pivotal events that will shape its future. On the 16th, shareholders must ...

The countdown has begun for Outlook Therapeutics, with the U.S. Food and Drug Administration setting a binding decision date of ...

A director at Outlook Therapeutics has put more than $5 million of his own money on the line, scooping up ...

Investor attention within the biotechnology space is increasingly focused on Outlook Therapeutics. The company is approaching several pivotal operational milestones ...

The biopharmaceutical company Outlook Therapeutics is approaching a pivotal transition, moving from clinical development into the commercial phase. This shift ...

The investment community is closely monitoring Outlook Therapeutics as it navigates a decisive period for its flagship ophthalmic drug. While ...

Investors are driving substantial gains for Outlook Therapeutics as the company achieves a critical regulatory breakthrough. The catalyst behind this ...

Today marks a pivotal juncture for biotech firm Outlook Therapeutics, as the U.S. Food and Drug Administration prepares to issue ...